Table 1. Baseline Characteristics of Integrating Pharmacogenetics in Clinical Care Study Participants.
| Characteristic | Participants, No. (%) | |
|---|---|---|
| Genotyping results known at baseline (n = 193) | Genotyping results known at 12 mo (n = 215) | |
| Age, mean (SD), y | 64.2 (7.8) | 63.9 (7.7) |
| Women | 9 (4.7) | 16 (7.4) |
| Non-White racea | 30 (15.5) | 26 (12.1) |
| Hispanic or Latino ethnicitya | 2 (1.0) | 6 (2.8) |
| Smokers | 59 (30.6) | 78 (36.3) |
| Meeting ACC-AHA statin criteriab | ||
| ASCVD | 52 (26.9) | 46 (21.4) |
| LDL-C >190 mg/dL | 5 (2.6) | 6 (2.8) |
| Diabetes | 47 (24.4) | 51 (23.7) |
| 10-y ASCVD risk ≥7.5% | 171 (88.6) | 196 (91.2) |
| SLCO1B1 genotype | ||
| Normal function (T/T) | 148 (76.7) | 140 (65.1) |
| Decreased function (T/C) | 40 (20.7) | 70 (32.6) |
| Poor function (C/C) | 5 (2.6) | 5 (2.3) |
Abbreviations: ACC-AHA, American College of Cardiology–American Heart Association; ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.
SI conversion factor: To convert LDL-C to mmol/L, multiply by 0.0259.
a
Race and ethnicity were collected from administrative data to assess generalizability of enrolled cohort to overall health care system population.
b
Categories sum to greater than 100% because criteria are not mutually exclusive (see text).